Berman Capital Advisors’s AnaptysBio ANAB Stock Holding History

Berman Capital Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-172	Closed	-$3K	–	1584
2020 Q2	$3K	Buy	+172	New	+$3.14K	﹤0.01%	1105

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's ANAB Position: Q3 2020 in Review

Berman Capital Advisors sold out of AnaptysBio (ANAB) in Q3 2020, closing a stake of 172 shares — an estimated $3K sold.

Berman Capital Advisors first reported a position in ANAB in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 132 funds tracked by Wall St. Rank hold ANAB as of Q3 2020.

Berman Capital Advisors reported no remaining AnaptysBio position as of Q3 2020 after selling out during the quarter.
Berman Capital Advisors sold 172 AnaptysBio shares in Q3 2020, an estimated $3K.
Berman Capital Advisors first reported a position in AnaptysBio in Q2 2020 and held it in 1 quarter.
Berman Capital Advisors's AnaptysBio position peaked at $3K in Q2 2020.
132 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2020.

Based on Berman Capital Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.